Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL23AP87 is a processed pseudogene related to the functional ribosomal protein L23a gene (RPL23A). Pseudogenes are DNA sequences that resemble functional genes but are typically non-functional due to mutations, lack of regulatory elements, or inability to produce active protein products[6][3]. While some ribosomal protein L23a pseudogenes have been studied for their expression in cancer tissues and may show regulatory or diagnostic associations[1], RPL23AP87 does not have evidence of biological function, disease relevance, or drug interactions. The parent gene, RPL23A, encodes a component of the large 60S ribosomal subunit, which is critical for cellular protein synthesis[7][3]. In summary, RPL23AP87 is a genomic artifact with no clear physiological or therapeutic relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 87 (RPL23AP87).